Financial results - EMINVEST PHARMACEUTICALS SRL

Financial Summary - Eminvest Pharmaceuticals Srl
Unique identification code: 17153971
Registration number: J2005001262406
Nace: 2042
Sales - Ron
2.949.851
Net Profit - Ron
417.057
Employees
32
Open Account
Company Eminvest Pharmaceuticals Srl with Fiscal Code 17153971 recorded a turnover of 2024 of 2.949.851, with a net profit of 417.057 and having an average number of employees of 32. The company operates in the field of Fabricarea parfumurilor şi a produselor cosmetice (de toaletă) having the NACE code 2042.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Eminvest Pharmaceuticals Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR 1.153.025 918.255 1.078.279 1.220.989 1.836.547 1.793.437 1.689.930 2.267.800 2.416.950 2.949.851
Total Income - EUR 1.154.072 919.212 1.099.804 1.207.471 1.869.394 1.810.854 1.714.904 2.309.375 2.441.129 2.957.694
Total Expenses - EUR 954.253 842.332 1.022.484 1.124.795 1.674.882 1.651.215 1.625.177 2.107.554 2.171.903 2.476.556
Gross Profit/Loss - EUR 199.819 76.880 77.321 82.675 194.512 159.639 89.728 201.820 269.226 481.138
Net Profit/Loss - EUR 162.739 47.260 54.695 68.586 167.196 138.423 77.157 174.396 233.772 417.057
Employees 22 21 25 0 29 31 31 32 31 32
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 22.7%, from 2.416.950 euro in the year 2023, to 2.949.851 euro in 2024. The Net Profit increased by 184.592 euro, from 233.772 euro in 2023, to 417.057 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Eminvest Pharmaceuticals Srl

Rating financiar

Financial Rating -
EMINVEST PHARMACEUTICALS SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Eminvest Pharmaceuticals Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Eminvest Pharmaceuticals Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Eminvest Pharmaceuticals Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Eminvest Pharmaceuticals Srl - CUI 17153971

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets 83.634 90.107 191.024 478.996 536.770 467.630 433.708 379.299 342.542 372.558
Current Assets 528.883 685.069 574.565 680.842 853.893 807.373 912.662 945.972 1.045.373 1.451.322
Inventories 78.107 136.251 131.593 154.942 192.248 301.089 251.318 390.165 318.320 477.971
Receivables 423.703 525.640 423.306 521.279 618.194 460.563 524.837 508.610 669.192 572.096
Cash 27.073 23.178 19.665 4.622 43.450 45.721 136.507 47.197 57.862 401.256
Shareholders Funds 162.793 47.491 54.958 68.844 234.749 351.000 363.750 480.642 543.596 758.897
Social Capital 45 223 219 215 253 248 243 243 243 241
Debts 450.139 727.983 729.294 1.109.457 1.167.965 929.876 984.670 845.091 845.013 1.065.798
Income in Advance 0 0 0 0 0 0 302 43 472 94
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "2042 - 2042"
CAEN Financial Year 2059
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 1.451.322 euro in 2024 which includes Inventories of 477.971 euro, Receivables of 572.096 euro and cash availability of 401.256 euro.
The company's Equity was valued at 758.897 euro, while total Liabilities amounted to 1.065.798 euro. Equity increased by 218.338 euro, from 543.596 euro in 2023, to 758.897 in 2024. The Debt Ratio was 58.4% in the year 2024.

Risk Reports Prices

Reviews - Eminvest Pharmaceuticals Srl

Comments - Eminvest Pharmaceuticals Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.